← Human Trials & Peer-Reviewed Studies
Effects of eight weeks of aerobic exercise and vitamin D supplementation on psychiatric comorbidities in men with migraine and vitamin D insufficiency: A randomized controlled clinical trial.
Plain-language guide to PMID 37146906 (2023): randomized controlled trial of Vitamin D, K2, Magnesium and Zinc, migraine.
Key Facts
- PMID
- 37146906
- Journal
- Journal of affective disorders
- Year
- 2023
- Study type
- Randomized Controlled Trial
- Authors
- Alipouri M et al. (4 authors)
- DOI
- 10.1016/j.jad.2023.04.108
What This Study Did, in Plain Language
What Was Tested
Researchers studied Vitamin D, K2, Magnesium and Zinc in the context of migraine in this randomized controlled trial publication.
This study investigated the effects of eight weeks of aerobic exercise and vitamin D supplementation on psychiatric comorbidities in men with migraine and vitamin D insufficiency.
Not having complete control of sun exposure and the diet were the limitations.
Who Took Part
PubMed tags the participants as men only.
Forty-eight participants took part in this randomized controlled clinical trial and were allocated into four groups: aerobic exercise and vitamin D (AE + VD), aerobic exercise and placebo (AE + Placebo), vitamin D (VD), and Placebo.
How the Study Was Run
In design terms this was a randomized and placebo-controlled study.
Because people in this Vitamin D, K2, Magnesium and Zinc study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The comparison arm used a placebo, so changes seen with Vitamin D, K2, Magnesium and Zinc could be set against what happens without it.
What Was Measured
Topics PubMed links to this paper include Vitamin D, Vitamins, Dietary Supplements, Vitamin D Deficiency, Exercise and Migraine Disorders.
Author keywords: Depression, Exercise training, Physical self-concept and Quality of sleep.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Vitamin D, K2, Magnesium and Zinc in people with migraine.
Its findings take up roughly 4 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2023 (Journal of affective disorders), a journal based in Netherlands.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, Migraine research.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.